Streetbeat News

Regulatory

JPM

Former President Donald Trump has proposed that presidents should have the power to influence the Federal Reserve’s interest rate decisions, potentially challenging the central bank’s political independence. Trump made this suggestion during a press conference in Palm Beach, Florida, arguing that the president should have a say in the Federal Reserve’s decisions. The Federal Reserve declined to comment on Trump’s remarks.

Portfolio Pulse from Benzinga Neuro

August 09, 2024 | 12:57 am

CINGW

Trading for CINGW was halted at 7:50:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:50 pm

CING

Trading for Cingulate Inc. (CING) was halted at 7:50:00 p.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:50 pm

CTXR

Citius Pharmaceuticals Inc (NASDAQ:CTXR) has received FDA approval for its skin cancer drug Lymphir, a year after an initial rejection. Lymphir is the first FDA-approved product for Citius and targets the interleukin-2 receptor on malignant T-cells and Tregs. The company plans to launch the drug in the U.S. within five months. The approval is based on a phase 3 trial showing a 36% overall response rate. CTXR stock closed lower by 1.76% at $0.88 on Thursday.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 9:41 pm

TRVN

Trevena, Inc. (NASDAQ:TRVN) announced a 1-for-25 reverse stock split effective August 13, 2024, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The stock will trade on a split-adjusted basis starting that day.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:34 pm

PROP

Prairie Operating Co. (NASDAQ:PROP) has submitted its second Oil and Gas Development Plan (OGDP), Genesis II, to the Colorado Energy and Carbon Management Commission (CECMC). The company received approval for the first 20 wellbores within the Genesis I OGDP. The Genesis II OGDP will develop up to 42 three-mile lateral wells in Weld County, Colorado, with a fully electrified drill rig and production facility. The CECMC hearing for Genesis II is expected in Q1 2025, with the project drill-ready by Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:32 pm

ORGO

Organogenesis Holdings Inc. (NASDAQ: ORGO) announced that it is on track to submit the Biologics License Application (BLA) for its ReNu product by the end of 2025. The company has completed enrollment in the second Phase 3 clinical trial ahead of expectations, with 594 patients enrolled. The FDA has indicated that two well-controlled Phase 3 trials are required for regulatory approval.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:13 pm

SPY

Federal Reserve's Goolsbee stated that the US economy is returning to more normal conditions, indicating potential stability in economic activities.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:01 pm

AXDX

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced the successful completion of its WAVE pre-clinical trial, which aims to deliver rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolated colonies. The WAVE system can report accurate results within 4.5 hours, potentially improving patient outcomes, reducing hospital costs, and combating antimicrobial resistance.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:00 pm

AMPL

Amplitude has provided its financial outlook for Q3 and FY24, with EPS and revenue estimates slightly below analyst expectations. The company also anticipates a negative impact from new US sanctions on Russia, affecting its receivables.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:42 pm